Phase II evaluation of RFT5-dgA [monoclonal antibody ricin chain A conjugate] immunotoxin in patients with metastatic melanoma.

Trial Profile

Phase II evaluation of RFT5-dgA [monoclonal antibody ricin chain A conjugate] immunotoxin in patients with metastatic melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2013

At a glance

  • Drugs Monoclonal antibody ricin chain A conjugate (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Jul 2012 Actual end date (1 Nov 2008) added as reported by ClincialTrials.gov.
    • 11 Jul 2012 Actual end date (1 Nov 2008) added as reported by ClincialTrials.gov.
    • 01 Nov 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top